ATE483816T1 - Systemisches virus/ligand genabgabemittel und gentherapie - Google Patents

Systemisches virus/ligand genabgabemittel und gentherapie

Info

Publication number
ATE483816T1
ATE483816T1 AT99959034T AT99959034T ATE483816T1 AT E483816 T1 ATE483816 T1 AT E483816T1 AT 99959034 T AT99959034 T AT 99959034T AT 99959034 T AT99959034 T AT 99959034T AT E483816 T1 ATE483816 T1 AT E483816T1
Authority
AT
Austria
Prior art keywords
virus
ligand
gene
gene therapy
delivery agent
Prior art date
Application number
AT99959034T
Other languages
English (en)
Inventor
Esther Chang
Kathleen Pirollo
Liang Xu
William Alexander
Original Assignee
Univ Georgetown
Synergene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown, Synergene Therapeutics Inc filed Critical Univ Georgetown
Application granted granted Critical
Publication of ATE483816T1 publication Critical patent/ATE483816T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99959034T 1998-11-19 1999-11-19 Systemisches virus/ligand genabgabemittel und gentherapie ATE483816T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10923698P 1998-11-19 1998-11-19
US12833099P 1999-04-08 1999-04-08
PCT/US1999/027365 WO2000029600A1 (en) 1998-11-19 1999-11-19 Systemic viral/ligand gene delivery system and gene therapy

Publications (1)

Publication Number Publication Date
ATE483816T1 true ATE483816T1 (de) 2010-10-15

Family

ID=26806780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99959034T ATE483816T1 (de) 1998-11-19 1999-11-19 Systemisches virus/ligand genabgabemittel und gentherapie

Country Status (10)

Country Link
EP (1) EP1131457B1 (de)
JP (2) JP5448283B2 (de)
CN (1) CN100572542C (de)
AT (1) ATE483816T1 (de)
AU (1) AU1628800A (de)
CA (1) CA2349238A1 (de)
DE (1) DE69942837D1 (de)
HK (1) HK1041498B (de)
PT (1) PT1131457E (de)
WO (1) WO2000029600A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10337770A1 (de) * 2003-08-14 2005-03-24 TransMIT Gesellschaft für Technologietransfer mbH Endothelzellspezifisches Gentransfersystem
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5378457A (en) 1981-12-24 1995-01-03 Virogenetics Corporation Interferon sensitive recombinant poxvirus vaccine
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
AU2112697A (en) * 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
EP0927044A4 (de) * 1996-04-16 1999-09-08 Immusol Inc Gerichtete viral vektoren
EP0973926A1 (de) * 1997-03-14 2000-01-26 Selective Genetics, Inc. Adenovirale vektoren mit verändertem tropismus

Also Published As

Publication number Publication date
HK1041498B (en) 2011-07-29
CN1326511A (zh) 2001-12-12
JP5448283B2 (ja) 2014-03-19
CN100572542C (zh) 2009-12-23
DE69942837D1 (de) 2010-11-18
WO2000029600A1 (en) 2000-05-25
CA2349238A1 (en) 2000-05-25
PT1131457E (pt) 2010-11-18
JP2002530086A (ja) 2002-09-17
EP1131457A1 (de) 2001-09-12
AU1628800A (en) 2000-06-05
EP1131457B1 (de) 2010-10-06
JP2010213726A (ja) 2010-09-30
HK1041498A1 (en) 2002-07-12

Similar Documents

Publication Publication Date Title
ATE200105T1 (de) Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen
TR199701071T2 (xx) Aktif madde ula�t�rmaya mahsus bile�ikler ve terkipler.
AU2002305450A1 (en) Proteomimetic compounds and methods
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
IL264439B1 (en) non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
ATE279430T1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
CY1114265T1 (el) Πρωτεϊνη συντηξης αλβουμινης
Shin et al. Enhanced local delivery of engineered IL-2 mRNA by porous silica nanoparticles to promote effective antitumor immunity
EP1226109A4 (de) Phenylamin-carbonsäure-verbindungen und zubereitungen zur verabreichung von wirkstoffen
ATE532860T1 (de) B7-ähnliche moleküle und deren anwendungen
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
EP1025217A4 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
BR9909978A (pt) Composição farmacêutica para administração parenteral, processo para tratamento de um paciente sofrendo de hemofilia, e, uso de uma partìcula coloidal
BR0108959A (pt) Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
WO2003012050A3 (en) Mitochondrial genome replenishment
ATE382697T1 (de) Mutierte version der arginin deiminase
DE10290072D2 (de) Modulare Transfektionssysteme
WO2004054607A3 (de) Stabile therapeutische proteine
FR2857267B1 (fr) Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
ATE483816T1 (de) Systemisches virus/ligand genabgabemittel und gentherapie
EP1466614A4 (de) Polypeptid, dessen konjugat doxorubicin enthält, und auf diesem basierende pharmazeutische zusammensetzung
BR0013228A (pt) Método e composições utilizados para modulação de angiogenese usando proteìna quinase raf e ras
PT866861E (pt) Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1131457

Country of ref document: EP